In the past, Parkinson’s disease was primarily considered a disorder of the nervous system, centered in the brain. However, ...

For the study, researchers analyzed data from 9,350 people with no previous history of Parkinson’s disease. They discovered that those who had mucosal damage had a 76 percent greater risk of ...

Development of vaccines against AIDS and sexually transmitted diseases is pursued using novel antigen delivery systems and combination of immunization routes to stimulate mucosal immunity in the ...

In one patient, active mucosal involvement was present at the ... Of note, patients with a disease duration of <2 years had higher healing rates compared with those with a disease duration ...

Understanding the communication between mucosal sites is fundamental to the next phase of disease characterization and vaccine development. Appreciation of the mucosal immune system as a global ...

A better understanding of this crosstalk may help us to develop more effective mucosal vaccines, as well as new therapeutic and preventive measures against inflammatory diseases. At the juncture ...

The Mucosal HIV and Immunobiology Center at the University of Alabama at Birmingham, established through the NIH's Digestive Diseases Research Development Center program, offers a unique opportunity ...

Parkinson’s disease may start in the gut, with gastrointestinal symptoms like constipation appearing years before ...

“Innovative therapeutics for autoimmune diseases of the intestinal mucosa have largely been dominated by injectable drugs. Our small molecule, OR-812, has the potential to offer IBD patients a ...

Our ability both to assess disease activity and predict outcomes in IBD using available scoring methods is still developing. Both validation of existing methods as well as additional tools that ...